Regeneus (ASX:RGS), a clinical-stage regenerative medicine technology company, today announced that the Australian Patent Office has granted a patent covering the use of cancer vaccine technology for the treatment of a range of cancers in humans and animals.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, announced today that John Martin, CEO, will present at Austrade's Mission on Regenerative Medicine Opportunities in Japan, on Monday 7 December in Tokyo and Wednesday 9 December in Kobe.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, announced today the commencement of a trial of its cancer vaccine technology, Kvax, in combination with chemotherapy as a treatment for canine lymphoma.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, announced today the commencement of a trial of its cancer vaccine technology, Kvax, in combination with chemotherapy as a treatment for canine lymphoma.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that it has secured exclusive rights to commercialise a breakthrough cell identification and selection technology that for the first time in the world allows high potency secreting stem cells to be identified and selected for the manufacture of next generation cell therapies.
iQ3Corp Ltd (ASX:iQ3) is pleased to announce that it has today been appointed to act as corporate advisor to the parties to the in Principal Agreement by iQnovate Limited (IQN) to acquire a 50% equity stake in Emedia Creative Pty Ltd (Emedia) and the proposed listing of Emedia on the ASX.
iQ3Corp Ltd (ASX:IQ3) are pleased to provide the Chairman's Address to Shareholders at the 2015 Annual General Meeting (AGM).
